Cardiovascular Disease

While cardiovascular disease may be common and commonly known to patients, they may not know some of the surprising factors in their diet and medical history that may actually be putting them at risk. What are some of the cardiovascular disease risk factors patients should know about?

The FDA has approved Trulicity (dulaglutide; Lilly) to reduce the risk of major adverse cardiovascular events (MACE; cardiovascular death, nonfatal myocardial infarction [MI], or nonfatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.

The FDA has authorized marketing of Caption Guidance software (Caption Health) to assist medical professionals in the acquisition of cardiac ultrasound images.

The Food and Drug Administration (FDA) has granted Orphan Drug designation to PIC1-dPEG24 (ReAlta Life Sciences) for the treatment of hypoxic-ischemic encephalopathy (HIE) in neonates.

Authors call for sharing of individual patient data to strengthen meta-analyses focused on safety.

The FDA has approved a new indication for Ozempic (semaglutide; Novo Nordisk) injection to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.

AstraZeneca is discontinuing a phase 3 trial evaluating Epanova (omega-3 carboxylic acids) in patients with mixed dyslipidemia who are at high risk of cardiovascular disease (CVD), as findings from the study showed the treatment was unlikely to be beneficial.

Reduced risk seen for total CVD, coronary heart disease incidence for men and women

The use of plasma infusion therapies (often called “vampire” treatments, in which people undergo infusions of a young donor’s blood) is on the rise across the United States.

For patients with an admitting diagnosis of acute coronary syndrome and/or acute decompensated heart failure, opioid prescription at discharge is not significantly associated with unplanned health care utilization or mortality but is associated with reduced odds of completed planned health care utilization.